Astria Therapeutics, Inc.

Astria Therapeutics, Inc. insiders are currently net buyers of ATXS stock, showing bullish sentiment over the past 90 days. Executives have purchased $51.6M while selling $247.3K, resulting in a positive net flow of $51.3M. This buying activity represents 100% of total transaction volume.

Astria Therapeutics, Inc. has 17 active insiders who have filed SEC Form 4 transactions in the past 90 days. Xontogeny Venture Fund, Lp Perceptive (Executive) leads with 1 transactions totaling $30.0M. Life Sciences Master Fund Ltd Perceptive (Executive) follows with 3 transactions worth $17.0M. Open-market purchases require insiders to invest their own capital, demonstrating genuine conviction.

The Insider Alignment Score measures the ratio of buying to selling activity on a 0-100 scale. Astria Therapeutics, Inc.'s current score of 100/100 indicates bullish insider sentiment. Scores above 60 suggest insiders are accumulating shares faster than selling, reflecting $51.6M in purchases versus $247.3K in sales.

The most recent insider transaction occurred on Jun 5, 2024, when Bate Kenneth (Executive) acquired 14,100 shares at $0.00 per share for $0. This appears to be a discretionary trade.

Based on SEC Form 4 filings from the past 90 days, ATXS insider trading sentiment is currently bullish with an Alignment Score of 100/100. The net insider flow of $51.3M reflects accumulation, with 100% of volume being purchases.

SEC Form 4 is the primary disclosure mechanism for insider trading at publicly traded companies like Astria Therapeutics, Inc.. Corporate insiders must file within two business days of any transaction, making it one of the most timely sources of executive sentiment. At ATXS, we track all Form 4 filings—currently showing 33 transactions from 17 insiders over 90 days.

A 10b5-1 plan allows Astria Therapeutics, Inc. executives to pre-schedule stock sales when they don't possess material non-public information. At ATXS, approximately 27% of recent transactions are 10b5-1 trades. The remaining 73% are discretionary trades, which may carry more informational value.

You can monitor Astria Therapeutics, Inc. (ATXS) insider trading activity on this page, which updates within hours of new SEC Form 4 filings. We track all 17 active insiders and provide real-time transaction feeds, the Alignment Score, 10b5-1 vs. discretionary breakdowns, and direct links to SEC EDGAR filings.

Our Alignment Score measures the ratio of insider buying to selling on a scale of 0-100. A score above 70 indicates strong bullish sentiment, while below 30 suggests bearish activity. Astria Therapeutics, Inc.'s current score of 100/100 indicates strong bullish sentiment with executives accumulating shares. This is calculated from $51.6M in purchases versus $247.3K in sales over 90 days, resulting in a net flow of $51.3M.

SEC Form 4 filings are mandatory reports that Astria Therapeutics, Inc. insiders must submit within 2 business days. Each filing includes the insider's name, relationship, transaction type, shares, and price. Transaction codes: P (purchase), S (sale), A (award), M (option exercise), G (gift). At ATXS, the most common type is "A" with 14 occurrences. The most recent Form 4 was filed on Jun 5, 2024 by Bate Kenneth.

Rule 10b5-1 allows corporate insiders to establish pre-scheduled trading plans when they don't possess material non-public information. At Astria Therapeutics, Inc., approximately 27% of recent transactions are executed under 10b5-1 plans, while 73% appear to be discretionary trades. This mix provides a balanced picture—some planned, others reflecting real-time decisions.